Interestingly, there is currently a trend toward tumors expressing SORT1 among HER2-positive tumors (77%) than among HER2-negative tumors (63%), whereas 59% of triple-negative breast cancers were positive [24]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.